Joris Vogels

Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto.

NIBC Bank NV engages in the provision of investment banking and financial services. The firm offers advises on mergers, acquisitions, financial policy, and property financing, lending, leveraged finance, and derivatives. It provides asset financing to corporate lending, leveraged finance, oil and gas services, infrastructure, real estate, and shipping Sector. The company was founded in 1945 and is headquartered in The Hague, the Netherlands.

Berk Management BV (BM), also known by their trade name as Berk Partners, is the private equity subsidiary of TIIN Capital Management BV in The Netherlands. The firm originated as Berk Holding in the 1970s, owned by Ben Pon. BM was established in 1990 when the holding was transformed into an investment firm and they created their first fund. Located in Abcoude, BM focuses on ownership transition opportunities within family-run firms. They specialize in MBOs and expansion financing. They also consider MBIs. The firm manages the Berk Partners funds.

ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands.

Cassini BV manufactures lenses. The private company is based in Delft, Netherlands. The CEO of the Dutch company is Jeroen Cammeraat.

Discus Dental LLC develops, manufactures and distributes dental products such as tooth whitening, oral hygiene, preventatives, and restoratives. The company was co-founded by William Dorfman and Robert Hayman on December 7, 1990 and is headquartered in Culver City, CA.

River 2 Renal Corp. develops novel therapies targeting orphan diseases in the renal space. The private company is based in New York, NY.

Dren Bio, Inc. operates as a biotechnology company. It focuses on protein engineering technologies for depletion of cells, protein aggregates, and other disease-causing agents. The company was founded by John Wesley and Nenad Tomasevic in 2019 and is headquartered in San Carlos, CA.

Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA.

HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US.

ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.

Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.

Symbiomix Therapeutics LLC develops medicines for women’s health infections and related diseases. It offers SYM-1219, a drug that contains secnidazole that facilitate administration as a single-dose oral therapy for various women's health infections including bacterial vaginosis. The company was founded by Jack Roberts, Steve Pomerantz and Joseph L. Amprey III in 2012 and is headquartered in Newark, NJ.

CardiacAssist, Inc. develops, manufactures and markets medical devices. The firm’s products include TandemLife Kit, TandemHeart Kit, TandemLung Kit, ProtekDuo Kit and educational videos. The company was founded by John C. Marous, Jr. and George J. Magovern in 1996 and is headquartered in Pittsburgh, PA.

Gynesonics, Inc. provides medical devices for women's health. It offers VizAblate System for the transcervical treatment of symptomatic uterine fibroids under intrauterine ultrasound guidance. The company was founded by Jessica grossman in 2005 and is headquartered in Redwood City, CA.

Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland.

Gimv Nederland BV (Gimv-Nederland) is the Netherlands-based private equity subsidiary of GIMV Corporate Investment, which in turn is a subsidiary of Gimv NV (XB: GIMB) in Belgium. Established in 1983, Gimv-Nederland was formerly known as Halder Invest BV and became part of the Gimv Group in 2000. The firm is located in The Hague with additional offices in Frankfurt and Antwerp. Their clients include fund of funds, insurance companies, banks, corporations and pension funds.